Acasti Pharma Statistics
Total Valuation
Acasti Pharma has a market cap or net worth of $26.79 million. The enterprise value is $9.96 million.
| Market Cap | 26.79M |
| Enterprise Value | 9.96M |
Important Dates
The last earnings date was Friday, June 21, 2024, before market open.
| Earnings Date | Jun 21, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
Acasti Pharma has 9.40 million shares outstanding.
| Shares Outstanding | 9.40M |
| Owned by Insiders (%) | 41.42% |
| Owned by Institutions (%) | 13.46% |
| Float | 5.87M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 0.59 |
| P/FCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 14.26, with zero debt.
| Current Ratio | 14.26 |
| Quick Ratio | 14.09 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | 17.12 |
Financial Efficiency
Return on equity (ROE) is -20.00% and return on invested capital (ROIC) is -20.82%.
| Return on Equity (ROE) | -20.00% |
| Return on Assets (ROA) | -17.10% |
| Return on Capital (ROIC) | -20.82% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$401,656 |
| Employee Count | 32 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | -1.34M |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -9.00% in the last 52 weeks. The beta is 1.62, so Acasti Pharma's price volatility has been higher than the market average.
| Beta (5Y) | 1.62 |
| 52-Week Price Change | -9.00% |
| 50-Day Moving Average | 2.92 |
| 200-Day Moving Average | 2.74 |
| Relative Strength Index (RSI) | 41.08 |
| Average Volume (20 Days) | 16,141 |
Short Selling Information
| Short Interest | 5,898 |
| Short Previous Month | 4,398 |
| Short % of Shares Out | 0.08% |
| Short % of Float | n/a |
| Short Ratio (days to cover) | 0.46 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -9.40M |
| Pretax Income | -10.74M |
| Net Income | -12.85M |
| EBITDA | -11.40M |
| EBIT | -11.41M |
| Earnings Per Share (EPS) | -$0.99 |
Balance Sheet
The company has $16.83 million in cash and no debt, giving a net cash position of $16.83 million or $1.79 per share.
| Cash & Cash Equivalents | 16.83M |
| Total Debt | n/a |
| Net Cash | 16.83M |
| Net Cash Per Share | $1.79 |
| Equity (Book Value) | 45.16M |
| Book Value Per Share | 4.80 |
| Working Capital | 16.33M |
Cash Flow
In the last 12 months, operating cash flow was -$9.02 million and capital expenditures $65,098, giving a free cash flow of -$8.96 million.
| Operating Cash Flow | -9.02M |
| Capital Expenditures | 65,098 |
| Free Cash Flow | -8.96M |
| FCF Per Share | -$0.94 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
Acasti Pharma does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -28.16% |
| Shareholder Yield | -28.16% |
| Earnings Yield | -47.98% |
| FCF Yield | -33.43% |
Analyst Forecast
The average price target for Acasti Pharma is $6.00, which is 110.53% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $6.00 |
| Price Target Difference | 110.53% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 1 |
| Revenue Growth Forecast (5Y) | n/a |
| EPS Growth Forecast (5Y) | n/a |
Stock Splits
The last stock split was on July 10, 2023. It was a reverse split with a ratio of 1:6.
| Last Split Date | Jul 10, 2023 |
| Split Type | Reverse |
| Split Ratio | 1:6 |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 2 |